BioSpace News Archive

Puma Biotechnology, Inc. announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor resistant, human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer at the 2024 American Society of Clinical Oncology Annual Meeting currently being held in Chicago.

Merus N.V. announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® Annual Meeting taking place in Chicago May 31-June 4, 2024.

Genmab A/S announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma.

Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations, after chemoradiotherapy compared to placebo after CRT.

Keymed Biosciences Inc. announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis has been released by way of oral presentation at the European Academy of Allergy and Clinical Immunology Congress 2024.

Mesoblast Limited, Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.

Immutep Limited announced that it has entered into a clinical trial collaboration and supply agreement with MSD, through a subsidiary, to evaluate eftilagimod alfa in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in a pivotal Phase III trial.

Innovent Biologics, Inc. delivered two oral presentations of its first-in-class anti-CLDN18.2/CD3 bispecific antibody for the treatment of advanced pancreatic cancer and gastric or gastroesophageal tumors at the 2024 American Society of Clinical Oncology Annual Meeting from clinical data of a Phase I study.

The annual meeting of the American Society of Clinical Oncology commenced on May 31st, Showcasing groundbreaking cancer research from around the world.

Dizal presented the latest data from the inaugural global pivotal study WU-KONG1 Part B of sunvozertinib in relapsed or refractory non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations at the 2024 American Society of Clinical Oncology Annual Meeting.